Alkem: Achieves 10.3% Year-Over-Year Growth In May 2025 📈💰🌟

 10 Jun 2025 09:41 AM

Alkem: Achieves 10.3% Year-Over-Year Growth In May 2025 📈💰🌟

I-Sec maintains Add on Alkem Laboratories, revises target price to Rs 5,900

 04 Jun 2025 09:11 AM

ICICI Securities maintains an Add call on Alkem Laboratories, revising the target price to Rs 5,900. The brokerage anticipates a revenue CAGR of 9.3% and a slight margin expansion for Alkem over the next few years. However, they have reduced EPS estimates for FY27E due to an anticipated higher tax rate, impacting valuation.

Alkem Lab: Ms. Jayanti Sinha sells 1.42% stake at a floor price of ₹4,850 in a block deal valued at ₹825 crore. 💰📉🏥

 03 Jun 2025 06:58 PM

Alkem Lab: Ms. Jayanti Sinha sells 1.42% stake at a floor price of ₹4,850 in a block deal valued at ₹825 crore. 💰📉🏥

Alkem Laboratories shares drop 5% after Q4 results. Should you buy, sell, or hold?

 30 May 2025 11:05 AM

Alkem Laboratories shares fell 5% after Q4FY25 results showed a modest 4.2% profit rise to Rs 306 crore and margin contraction to 12.4%. While Jefferies downgraded the target to Rs 4,460 citing weak margins, Nomura maintained a ‘Buy’ with a Rs 5,430 target. The company expects high single-digit revenue growth in FY26 and rising tax rates in FY27.

ALKEM LABS: CO IS PLANNING TO FILE EIGHT TO NINE PRODUCTS IN THE US MARKET || CO IS HOPEFUL ABOUT LAUNCHING AT LEAST FIVE TO SIX NEW PRODUCTS THIS YEAR - CONCALL UPDATE

 30 May 2025 08:56 AM

ALKEM LABS: CO IS PLANNING TO FILE EIGHT TO NINE PRODUCTS IN THE US MARKET || CO IS HOPEFUL ABOUT LAUNCHING AT LEAST FIVE TO SIX NEW PRODUCTS THIS YEAR - CONCALL UPDATE

ALKEM LABS: CO PLANS TO ACHIEVE RS. 450 CR TO 500 CR OF SALES FROM CDMO BUSINESS OVER THE NEXT THREE YEARS AT FULL CAPACITY UTILIZATION || CO EXPECTS A 1.5% TO 2% VOLUME GROWTH IN THE CURRENT FINANCIAL YEAR - CONCALL UPDATE

 30 May 2025 08:55 AM

ALKEM LABS: CO PLANS TO ACHIEVE RS. 450 CR TO 500 CR OF SALES FROM CDMO BUSINESS OVER THE NEXT THREE YEARS AT FULL CAPACITY UTILIZATION || CO EXPECTS A 1.5% TO 2% VOLUME GROWTH IN THE CURRENT FINANCIAL YEAR - CONCALL UPDATE

ALKEM LABS: CO EXPECTS TO LAUNCH 5-6 NEW PRODUCTS THIS YEAR || CO IS CONFIDENT ABOUT DELIVERING GROWTH, UNLESS THERE ARE MARKET UPSWINGS, AND EXPECTS THE MARKET TRENDS TO BE MORE STABLE NOW - CONCALL UPDATE

 30 May 2025 08:53 AM

ALKEM LABS: CO EXPECTS TO LAUNCH 5-6 NEW PRODUCTS THIS YEAR || CO IS CONFIDENT ABOUT DELIVERING GROWTH, UNLESS THERE ARE MARKET UPSWINGS, AND EXPECTS THE MARKET TRENDS TO BE MORE STABLE NOW - CONCALL UPDATE

ALKEM LABS: EBITDA MARGINS ARE EXPECTED TO REMAIN SIMILAR TO 19.5% FOR THIS FINANCIAL YEAR || REVENUE GROWTH IS EXPECTED TO BE WITHIN THE RANGE OF 7% TO 8% FOR THE COMING YEAR, WITH POTENTIAL FOR SLIGHTLY MORE THAN THAT - CONCALL UPDATE

 30 May 2025 08:52 AM

ALKEM LABS: EBITDA MARGINS ARE EXPECTED TO REMAIN SIMILAR TO 19.5% FOR THIS FINANCIAL YEAR || REVENUE GROWTH IS EXPECTED TO BE WITHIN THE RANGE OF 7% TO 8% FOR THE COMING YEAR, WITH POTENTIAL FOR SLIGHTLY MORE THAN THAT - CONCALL UPDATE

ALKEM LAB: CO'S FULL YEAR NON US BUSINESS GROWTH AT 8.7% VS GUIDANCE 13 - 14%

 29 May 2025 02:24 PM

ALKEM LAB: CO'S FULL YEAR NON US BUSINESS GROWTH AT 8.7% VS GUIDANCE 13 - 14%

ALKEM LABORATORIES: CO FULL YEAR EBITDA MARGIN AT 19.38% VS GUIDANCE OF 19%

 29 May 2025 02:03 PM

ALKEM LABORATORIES: CO FULL YEAR EBITDA MARGIN AT 19.38% VS GUIDANCE OF 19%